Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Interest & Investment Income (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Interest & Investment Income for 16 consecutive years, with $91967.0 as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 13.78% to $91967.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $476748.0 through Dec 2025, up 42.55% year-over-year, with the annual reading at $476748.0 for FY2025, 42.55% up from the prior year.
  • Interest & Investment Income hit $91967.0 in Q4 2025 for Cumberland Pharmaceuticals, down from $131583.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $131583.0 in Q3 2025 to a low of $5426.0 in Q1 2021.
  • Historically, Interest & Investment Income has averaged $61126.6 across 5 years, with a median of $59451.0 in 2023.
  • Biggest five-year swings in Interest & Investment Income: crashed 81.85% in 2021 and later skyrocketed 585.1% in 2022.
  • Year by year, Interest & Investment Income stood at $6670.0 in 2021, then surged by 585.1% to $45696.0 in 2022, then skyrocketed by 77.26% to $81000.0 in 2023, then soared by 31.69% to $106667.0 in 2024, then dropped by 13.78% to $91967.0 in 2025.
  • Business Quant data shows Interest & Investment Income for CPIX at $91967.0 in Q4 2025, $131583.0 in Q3 2025, and $127489.0 in Q2 2025.